Evaluating The Therapeutic Effect of 2-Nitroimidazole on Toxoplasma gondii: An In vitro and In vivo Study Using...

Toxoplasmosis, caused by the protozoan parasite Toxoplasma gondii, remains a significant health concern due to its widespread prevalence and severe impact on immunocompromised individuals. Current treatments are limited, necessitating the exploration of new therapeutic agents.

This study aimed to evaluate the efficacy and safety of 2-nitroimidazole as a potential treatment for toxoplasmosis in BALB/c mice, comparing its effects with the standard treatment, sulfadiazine.

In vitro assays were conducted to determine the half-maximal inhibitory concentration (IC50) of 2-nitroimidazole and sulfadiazine against T. gondii tachyzoites. The MTT assay was used to assess the cytotoxicity of 2-nitroimidazole on macrophages. In vivo experiments involved treating BALB/c mice infected with T. gondii with either 2-nitroimidazole or sulfadiazine, monitoring survival rates and therapeutic outcomes.

In vitro results revealed IC50 values of 5.43 μM for 2-nitroimidazole and 2.99 μM for sulfadiazine, indicating potent anti-tachyzoite activity. The MTT assay showed that 2-nitroimidazole had low cytotoxicity, with significant cell viability even at higher concentrations. Based on the MTT assay findings, 40 μM of 2-nitroimidazole showed the highest level of toxicity towards macrophages. Furthermore, flow cytometry analysis revealed that this compound induced apoptosis in approximately 58.9% of tachyzoites. In vivo, all mice in the control group died by the eighth day. Treatment with sulfadiazine resulted in two mice surviving until the 14th day, while 2-nitroimidazole treatment saw one mouse surviving to the same day. These findings suggest that 2-nitroimidazole has comparable efficacy to sulfadiazine with potentially fewer side effects.

The study demonstrates that 2-nitroimidazole is a promising candidate for the treatment of toxoplasmosis, exhibiting strong anti-parasitic activity and low cytotoxicity. Further research is warranted to optimize dosing regimens and explore combination therapies to enhance its therapeutic potential.